作者
Dana J Holger, Nicholas S Rebold, Sara Alosaimy, Taylor Morrisette, Abdalhamid Lagnf, Ana Christine Belza, Ashlan J Kunz Coyne, Amer El Ghali, Michael P Veve, Michael J Rybak
发表日期
2022/10
期刊
Infectious Diseases and Therapy
卷号
11
期号
5
页码范围
1965-1980
出版商
Springer Healthcare
简介
Introduction
Infections caused by multidrug-resistant (MDR), extensively drug-resistant (XDR), and difficult-to-treat (DTR) Pseudomonas aeruginosa are increasingly challenging to combat. Ceftolozane–tazobactam (C/T) is a novel β-lactam–β-lactamase inhibitor combination now commonly used to treat MDR and XDR P. aeruginosa. Lower respiratory tract infections (LRTIs) remain the most common source of infection caused by MDR/XDR P. aeruginosa. Comparative effectiveness studies to date have been limited by the type of comparator agents (i.e., aminoglycosides and polymyxins) and the inclusion of multiple infection sources (i.e., urinary tract, abdominal, skin and soft tissue, etc.).
Methods
We performed a multicenter, retrospective analysis of adults with LRTI caused by MDR or XDR P. aeruginosa admitted from January 2014 to December 2019. We aimed to compare clinical outcomes between patients who …
学术搜索中的文章
DJ Holger, NS Rebold, S Alosaimy, T Morrisette… - Infectious Diseases and Therapy, 2022